Brain health dietary supplements are a heavily marketed $3.2 billion industry: here’s how to talk with patients about supplements and other pseudomedicine interventions for dementia that lack credible data. (JAMA)
What are the germs in your gut telling your brain? (New York Times)
Thymectomy continued to provide clinical benefits to myasthenia gravis patients for as long as 5 years, an extension of the MGTX trial showed. (The Lancet Neurology)
Sephin1, a small molecule derivative of the antihypertensive drug guanabenz (Wytensin), delayed the loss of myelin and postponed onset of clinical symptoms in a mouse model of multiple sclerosis. (Brain)
A first-in-world trial of focused ultrasound to control treatment-resistant epilepsy began this month, Ohio State University announced.
High levels of the satiety hormone cholecystokinin were tied to less likelihood of developing Alzheimer’s. (Neurobiology of Aging)
Despite risks, most parents think opioids are more effective at managing their child’s pain after surgery or a broken bone than alternatives, a survey commissioned by the American Society of Anesthesiologists found.
The number of concussions in NFL games and practices fell 23.8% in 2018, the league reported. (ESPN)
How brain death is determined varies among doctors, with nearly one in four academic physicians saying they received no training in brain death assessment. (Neurology)
Which epilepsy patients will experience an adverse psychiatric effect from levetiracetam (Keppra)? Two new models may help predict that. (JAMA Neurology)
Source: MedicalNewsToday.com
